{"symbol":"LLY","fiscalQuarter":"Q2-2026","reportDate":"2026-08-05","reportTime":"BMO","status":"upcoming","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q2-2026","preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a major player in the pharmaceuticals sector, focusing on developing innovative medicines for various health conditions, including diabetes and cancer. With a market cap of $1,012 billion, the company is significant in the healthcare industry and plays a crucial role in addressing global health challenges.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and will help investors gauge financial performance this quarter.","consensus":"Not available"},{"name":"Revenue Growth","why":"Revenue growth will provide insights into the company's sales performance and market demand for its products.","consensus":"Not available"},{"name":"Market Share in Key Therapeutic Areas","why":"Understanding market share in critical areas like diabetes and oncology will highlight competitive positioning.","consensus":"Not available"}],"lastQuarterRecap":{"summary":"In Q1-2026, Eli Lilly reported an EPS of $8.55, significantly beating estimates by 21.07%. The stock reacted positively, gaining 9.80% the following day.","promises":["Continued focus on innovation in diabetes and cancer treatments.","Commitment to expanding market presence in emerging markets.","Plans to enhance operational efficiency and reduce costs."]},"wallStreetExpectations":{"summary":"Overall, analysts expect Eli Lilly to continue its strong performance, driven by innovative product offerings and market expansion. However, there are concerns about potential regulatory challenges and competition.","bullCase":"If Eli Lilly can maintain its growth trajectory and deliver strong EPS, it may further solidify its market leadership and attract more investors.","bearCase":"On the other hand, if the company faces setbacks in product approvals or market share erosion, it could lead to a negative reaction from investors."},"optionsSignal":{"impliedMove":"8.56%","context":"The options market is pricing in an expected move of about 8.56%, indicating that traders anticipate significant volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+21.07%","reaction":"+9.80%"},{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"},{"quarter":"Q1-2025","epsSurprise":"-5.01%","reaction":"-11.66%"}],"pivotalQuestions":[{"question":"What is the projected EPS for this quarter?","whyItMatters":"EPS is a critical measure of profitability, and exceeding expectations could lead to a positive market reaction."},{"question":"How is Eli Lilly addressing competition in its key therapeutic areas?","whyItMatters":"Understanding the competitive landscape will help investors assess the company's growth potential and market sustainability."}],"thesisBreakLevels":{"bullTrigger":"A reported EPS above $8.55 would confirm strong performance and investor confidence.","bearTrigger":"An EPS below $7.06 would signal potential challenges and could lead to a sell-off.","context":"The market is closely watching Eli Lilly's ability to sustain its growth amid increasing competition and regulatory scrutiny."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests a potential stock increase of around 3.77%, confirming strong operational performance.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss could lead to a decline of about 8.97%, reflecting investor disappointment and concerns over future growth."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Eli Lilly's ability to innovate and capture market share in key therapeutic areas, especially given recent successes.","supportingPoints":["The company has consistently beaten EPS estimates, indicating strong operational execution.","Options pricing suggests a significant move, which may reflect underlying confidence in the company's growth prospects."],"riskToConsensus":"If Eli Lilly's new product launches show stronger-than-expected demand, it could significantly alter market perceptions."},"whatToListenFor":["Details on new product launches and their expected market impact.","Updates on regulatory approvals and any potential delays.","Insights into competitive positioning and market share trends.","Management's outlook on future earnings and growth strategies.","Any commentary on cost management and operational efficiencies."],"metaDescription":"Eli Lilly (LLY) reports Q2 2026 earnings August 5. Analysts expect strong performance amid competitive pressures. Here's what to watch."}}